Immatics N.V.
Business
Immatics N.V. is a clinical-stage biopharmaceutical company developing precision immunotherapies targeting PRAME, an intracellular protein expressed in more than 50 cancers. The company's pipeline comprises TCR-based cell therapies (anzu-cel for melanoma, IMA203CD8 for solid tumors) and off-the-shelf bispecific T-cell engagers (IMA402 targeting PRAME, IMA401 targeting MAGEA4/8), deployed across multiple cancer indications in Phase 1–3 trials. Immatics manufactures cell therapies in-house at its Stafford, Texas facility and partners with contract manufacturers for bispecifics, while pursuing regulatory approvals in the U.S. and EU.
Summary from 20-F filed 2026-03-05
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-196.45M |
| Total assets | $562.34M |
| Total liabilities | — |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Immatics N.V.'s CIK number?
Immatics N.V.'s SEC CIK number is 0001809196 (1809196). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Immatics N.V.'s SEC filings?
All of Immatics N.V.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.